Fact Source: Financial Supervisory Service DART / 2026-06-09
Disclosure Type: Manufacturing Agreement (Amendment)
💡 3-Second Summary
Samsung Biologics has amended its contract manufacturing agreement with a European-based pharmaceutical company upon the client’s request, increasing the total contract value from KRW 349.9B to KRW 400.7B.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Reason for Amendment: Modification of contract value as requested by the client.
- Contract Details (Contract Manufacturing Agreement):
- Contract Value: (Pre-amendment) KRW 349,972,700,000 ➔ (Post-amendment) KRW 400,715,042,000 (Increased by KRW 50,742,342,000)
- Ratio to Sales: (Pre-amendment) 7.70% ➔ (Post-amendment) 8.81% (Compared to the FY2024 consolidated sales of KRW 4,547,322,176,421)
- Value in USD: Increased by USD 34,290,000 from the previous USD 236,500,000, bringing the new fixed total to USD 270,790,000 (Applying the initial FX rate of 1,479.80 KRW/USD as of March 13, 2026).
- Contract Term & Confidentiality Period: 2025-07-31 – 2032-03-13 (No changes)
- Counterparty: A pharmaceutical company located in Europe (Identity undisclosed until March 13, 2032, due to business confidentiality).
- Note on Execution: This contract was originally signed in August 2025 but was not disclosed at that time as it fell below the regulatory reporting threshold. It was initially disclosed on March 13, 2026, when the minimum purchase volume was finalized upon fulfilling the contract terms.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This regulatory filing outlines a scale modification for an existing supply agreement with a European pharmaceutical firm. Following a client-initiated request, the contract value has been revised upward by USD 34.29M (approximately KRW 50.7B), driving the total cumulative value above the KRW 400B threshold. The text of the filing does not state the specific operational or strategic drivers behind this pricing adjustment.
From a financial standpoint, the ratio against baseline sales shifted from 7.70% to 8.81%, indicating a incremental expansion in potential revenue recognition scale over the term. However, market participants should note that both the contract value and the final expiration date (March 13, 2032) remain subject to further modifications based on bilateral agreements. Furthermore, as the counterparty’s identity remains masked until 2032 under confidentiality clauses, evaluating partner-specific risks directly from this document is limited.
📝 Editor’s Comment (by K-STOCK Editor)
A European supply contract, which was initially disclosed in March 2026 following the finalization of its minimum purchase volume, has been adjusted upward within approximately three months upon the client’s request. The total finalized value is now fixed at USD 270.79M, representing 8.81% of the company’s FY2024 consolidated revenue. Because the filing attributes the amendment strictly to a “client request” without details on specific unit price changes or production parameters, the underlying causes remain unstated. Given the extended timeline through 2032, market participants may track ongoing quarterly implementation status while recognizing that long-term terms can potentially be re-adjusted later.
📢 Disclaimer & Source Information
Source: This content was structured and newly generated based on official data submitted to the Financial Supervisory Service electronic disclosure system (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
